Original Article

Improved GI Tolerability with Monthly Ibandronate in Women Previously Using Weekly Bisphosphonates

Objective:This subanalysis of CURRENT, an open-label, 6-month, multicenter study, assesses changes in gastrointestinal (GI) tolerability with once-monthly oral ibandronate in women who switched from once-weekly bisphosphonates and had reported GI symptoms with their previous weekly bisphosphonate regimen.Methods:Postmenopausal women currently taking a weekly bisphosphonate switched to 150 mg monthly ibandronate. At…